NDA 018147 · Pfizer
Feldene
Piroxicam · Oral
NovelLast checked: Nov 19, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Apr 6, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
31
12 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 6, 1982 Original approval · Type 1 - New Molecular Entity
2 products under this application
- FELDENE · PIROXICAM 10MG · CAPSULE, ORAL · Prescription · TE AB
- FELDENE · PIROXICAM 20MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Piroxicam" as an intervention, any sponsor and status, largest first.
- Topical Piroxicam vs Soulagel in the Treatment of Acute Extremity Pain After Emergency Department DischargePivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT05054023 · 1,525 participants · Start Oct 21, 2021 · Primary completion Mar 21, 2022
Drug: Soulagel®; Arthrosyl® · For: Acute Pain
Sites: Monastir, Tunisia
- NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain ManagementPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT03222518 · 1,500 participants · Start Mar 1, 2017 · Primary completion Nov 1, 2018
Drug: Paracetamol; NSAID and 1 more · For: Acute Pain Due to Trauma
Sites: Monastir, Tunisia
- Rct Assessing Pregnancy - Piroxicam for Ec With LevonorgestrelPivotal-lookingNot yet recruiting
University of UtahAcademic, hospital or other
NCT07449299 · 1,458 participants (planned) · Start Mar 2027 · Primary completion Jun 2031
Drug: Levonorgestrel 1.5 mg and Piroxicam 40 mg; Oral LNG + Placebo · For: Emergency Contraception; Contraception; COX-2 Inhibitor
- Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal ColicsPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02304783 · 1,400 participants · Start Jan 2014 · Primary completion Jun 2021
Drug: Piroxicam; Placebo and 1 more · For: Renal Colic
Sites: Monastir, Tunisia
- Multi-Centre European Photopatch Test StudyPivotal-lookingCompleted
NHS TaysideGovernment (non-federal)
NCT00530387 · 1,000 participants · Start Jul 2008 · Primary completion Jul 2011
Drug: 19 organic sunscreen filters and 5 topical NSAIDs · For: Dermatitis, Photocontact
Sites: Dundee, United Kingdom
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency ContraceptionPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06727734 · 980 participants (planned) · Start Jan 18, 2025 · Primary completion Sep 2027
Drug: Levonorgestrel; Piroxicam and 4 more · For: Contraception
Sites: Hong Kong, Hong Kong
- Piroxicam and Levonorgestrel Co-treatment for Emergency ContraceptionPivotal-lookingCompleted
Dr. Hang Wun Raymond LiAcademic, hospital or other
NCT03614494 · 860 participants · Start Aug 20, 2018 · Primary completion Oct 5, 2022
Drug: Piroxicam 40 mg; Levonorgestrel 1.5mg · For: Emergency Contraception
Sites: Hong Kong, Hong Kong · 2 sites in all
- Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal ColicsPivotal-lookingRecruiting
University of MonastirAcademic, hospital or other
NCT05722782 · 500 participants (planned) · Start Jul 1, 2023 · Primary completion Jun 2027
Drug: Piroxicam; Acetaminophen and 1 more · For: Renal Colic
Sites: Monastir, Tunisia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Tawfik AG, Gomez-Lumbreras A, Del Fiol G, et al. · Clin Pharmacol Ther 2026 · Systematic Review, Meta-Analysis
- Non-steroidal anti-inflammatory drugs for chronic low back pain.
Enthoven WT, Roelofs PD, Deyo RA, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
Zeng C, Wei J, Persson MSM, et al. · Br J Sports Med 2018 · Systematic Review, Network Meta-Analysis
- Topical NSAIDs for acute musculoskeletal pain in adults.
Derry S, Moore RA, Gaskell H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).
Castellsague J, Riera-Guardia N, Calingaert B, et al. · Drug Saf 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Do COX-inhibitors improve emergency contraception efficacy?
· Drug Ther Bull 2024 · Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.